Pfizer and BioNTech ‘s BNT162b2 Receive Health Canada Authorization to Combat COVID-19
Shots:
- Health Canada has granted authorization under interim order for the emergency use of BNT162b2. The distribution of the vaccine in Canada will be prioritized according to the populations identified in guidance from the NACI
- BioNTech will hold the regulatory approval in Canada while Pfizer will have the commercialization rights. The approval is based on data that was filed through the rolling submission regulatory pathway and data from the P-l/ll clinical trial that began recruiting in Jul’2020 & enrolled ~44-000 patients across ~150 sites in multiple countries
- The companies will supply ~20M doses of vaccine to Canada through 2021
Ref: PRNewswire | Image: Bloomberg Quint
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com